Inventor · disambiguated record
Leonardus H. T. Van Der Ploeg
Also filed as: VAN DER PLOEG LEONARDUS · VAN DER PLOEG LEONARDUS H · VAN DER PLOEG LEONARDUS H T
47 granted patents·42 pending applications·1,005 citations·filing 1994–2025
98Inventor score
Top patents by PatentIndex Score
89 records- 0198US9732031B2Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropionDEUTERX LLC·Filed 2014·Granted Aug 15, 2017·121 cites·9 claims
- 0297US5824837AExpression of human interleukin-1β in a transgenic animalMERCK & CO INC·Filed 1994·Granted Oct 20, 1998·150 cites·3 claims
- 0396US6410548B2Spiropiperidine derivatives as melanocortin receptor agonistsMERCK & CO INC·Filed 2001·Granted Jun 25, 2002·71 cites·11 claims
- 0496US6350760B1Substituted piperidines as melanocortin-4 receptor agonistsMERCK & CO INC·Filed 2000·Granted Feb 26, 2002·102 cites·25 claims
- 0593US6211428B1Transgenic mouse expressing a familial form of human amyloid precursor proteinMERCK & CO INC·Filed 1995·Granted Apr 3, 2001·165 cites·6 claims
- 0690US12285460B2Pharmaceutical compositionsRHYTHM PHARMACEUTICALS INC·Filed 2021·Granted Apr 29, 2025·1 cites·11 claims
- 0788US11129869B2Pharmaceutical compositionsRHYTHM PHARMACEUTICALS INC·Filed 2014·Granted Sep 28, 2021·5 cites·24 claims
- 0888US11123336B25-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the samePOXEL SA·Filed 2019·Granted Sep 21, 2021·2 cites·21 claims
- 0988US6294534B1Spiropiperidine derivatives as melanocortin receptor agonistsMERCK & CO INC·Filed 1999·Granted Sep 25, 2001·75 cites·15 claims
- 1086US10954268B2Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriersRHYTHM PHARMACEUTICALS INC·Filed 2019·Granted Mar 23, 2021·1 cites·18 claims
- 1186US10858399B2Peptide compositionsRHYTHM PHARMACEUTICALS INC·Filed 2018·Granted Dec 8, 2020·2 cites·20 claims
- 1286US10196425B2Peptide compositionsRHYTHM PHARMACEUTICALS INC·Filed 2014·Granted Feb 5, 2019·7 cites·27 claims
- 1386US6693184B1DNA molecules encoding splice variants of the human melanocortin 1 receptor proteinMERCK & CO INC·Filed 2001·Granted Feb 17, 2004·12 cites·18 claims
- 1486US6187992B1Transgenic mouse having a disrupted amyloid precursor protein geneMERCK & CO INC·Filed 1999·Granted Feb 13, 2001·99 cites·12 claims
- 1584US2025188124A1Peptide compositionsRHYTHM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1684US2024190914A1Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriersRHYTHM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1783US10265305B25-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the samePOXEL SA·Filed 2017·Granted Apr 23, 2019·2 cites·9 claims
- 1883US10188639B2Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazoneDEUTERX LLC·Filed 2015·Granted Jan 29, 2019·3 cites·20 claims
- 1982US11049492B2Systems and methods for transposing spoken or textual input to musicYAO THE BARD LLC·Filed 2020·Granted Jun 29, 2021·3 cites·33 claims
- 2082US2024417368A1Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropionDEUTERX LLC·Filed 2024·Application pending·0 cites
- 2180US6511827B1Nucleotide encoding human galanin receptor 3 (GALR3)MERCK & CO INC·Filed 2000·Granted Jan 28, 2003·5 cites·8 claims
- 2280US2025195606A1Method of treating melanocortin-4 receptor pathway-associated disordersRHYTHM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2379US6835548B2Isoforms of mouse serotonin 5-HT2c receptorMERCK & CO INC·Filed 2002·Granted Dec 28, 2004·6 cites·2 claims
- 2478US11918569B25-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the samePOXEL SA·Filed 2021·Granted Mar 5, 2024·0 cites·28 claims
- 2578US7163799B2Neuromedin U receptor NMUR2 and nucleotides encoding itMERCK & CO INC·Filed 2001·Granted Jan 16, 2007·7 cites·1 claims
- 2678US2022213023A1Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropionDEUTERX LLC·Filed 2022·Application pending·0 cites
- 2777US2022226425A1Method of treating melanocortin-4 receptor pathway-associated disordersRHYTHM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2876US11702448B2Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriersRHYTHM PHARMACEUTICALS INC·Filed 2020·Granted Jul 18, 2023·0 cites·11 claims
- 2976US5648222AMethod for preserving cells, and uses of said methodUNIV COLUMBIA·Filed 1994·Granted Jul 15, 1997·39 cites·13 claims
- 3076US2025268879A1Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazonePOXEL SA·Filed 2025·Application pending·0 cites
- 3174US2023218595A1Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2,4-diones for treatment of medical disordersDEUTERX LLC·Filed 2022·Application pending·0 cites
- 3273US11141411B2Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazonePOXEL SA·Filed 2018·Granted Oct 12, 2021·0 cites·18 claims
- 3373US5830433ARadiolabeled growth hormone secretagogueMERCK & CO INC·Filed 1996·Granted Nov 3, 1998·26 cites·12 claims
- 3473US2021387940A1Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropionDEUTERX LLC·Filed 2021·Application pending·0 cites
- 3573US2022193055A1Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazonePOXEL SA·Filed 2021·Application pending·0 cites
- 3672US12263202B2Method of treating melanocortin-4 receptor pathway-associated disordersCHARITE—UNIVERSITAETSMEDIZIN BERLIN·Filed 2021·Granted Apr 1, 2025·0 cites·21 claims
- 3772US12077612B2Peptide compositionsRHYTHM PHARMACEUTICALS INC·Filed 2020·Granted Sep 3, 2024·0 cites·6 claims
- 3871US6495665B1Isoforms of mouse serotonin 5-HT2C receptorMERCK & CO INC·Filed 2000·Granted Dec 17, 2002·1 cites·2 claims
- 3971US2024212667A1Systems and methods for transposing spoken or textual input to musicRIFFIT INC·Filed 2024·Application pending·0 cites
- 4070US2025082717A1Compositions for treating kidney diseaseRHYTHM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 4169US6639123B1Melanocortin-3 receptor deficient cells, non-human trangenic animals and methods of selecting compounds which regulate body weightMERCK & CO INC·Filed 2000·Granted Oct 28, 2003·10 cites·5 claims
- 4267US2022362220A15-deutero-thiazolidine-2,4-dione compounds and methods of treating medical disorders using samePOXEL SA·Filed 2020·Application pending·0 cites
- 4366US2020253937A15-deutero-thiazolidine-2,4-dione compounds and methods of treating medical disorders using samePOXEL SA·Filed 2019·Application pending·0 cites
- 4462US6004762AMethod for preserving cells, and uses of said methodTRUATEES OF COLUMBIA UNIVERSIT·Filed 1997·Granted Dec 21, 1999·28 cites·2 claims
- 4562US2023197058A1Systems and methods for transposing spoken or textual input to musicRIFFIT INC·Filed 2023·Application pending·0 cites
- 4661US2021169969A1Compositions for treating kidney diseaseVAN DER PLOEG LEONARDUS H T·Filed 2019·Application pending·0 cites
- 4761US2020239457A15-deutero-thiazolidinyldione compounds and methods of treating medical disorders using samePOXEL SA·Filed 2019·Application pending·0 cites
- 4860US7029865B2DNA molecules encoding the melanocortin 4 receptor protein from rhesus monkeyMERCK & CO INC·Filed 2003·Granted Apr 18, 2006·0 cites·4 claims
- 4960US2017369420A1Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropionDEUTERX LLC·Filed 2017·Application pending·0 cites
- 5060US2018125827A15-deutero-thiazolidine-2,4-dione compounds and methods of treating medical disorders using sameDEUTERX LLC·Filed 2017·Application pending·0 cites
Showing the top 50 of 89 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →